Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 10/20 | 0.67 |
| ▸ | TDO2 | P48775 | 2/20 | 0.66 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | CDC25A | P30304 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17651949 | 0.89 | IDO1 (0.67) | IDO1TDO2EGFRCDC25A | |
| SCHEMBL16135431 | 0.85 | IDO1 (0.63) | IDO1TDO2EGFRALDH1A1MEN1 | |
| SCHEMBL16135366 | 0.83 | IDO1 (0.61) | IDO1TDO2ALDH1A1MEN1KMT2A | |
| SCHEMBL16135330 | 0.82 | IDO1 (0.57) | IDO1TDO2ALDH1A1 | |
| SCHEMBL16135335 | 0.82 | IDO1 (0.98) | IDO1TDO2 | |
| SCHEMBL17651958 | 0.81 | TDO2 (0.63) | IDO1TDO2 | |
| SCHEMBL17665359 | 0.81 | IDO1 (0.68) | IDO1TDO2ALDH1A1MEN1KMT2A | |
| SCHEMBL16135400 | 0.81 | IDO1 (1.00) | IDO1TDO2 | |
| SCHEMBL16135373 | 0.81 | IDO1 (0.61) | IDO1TDO2ALDH1A1MEN1KMT2A | |
| SCHEMBL17665360 | 0.80 | IDO1 (0.57) | IDO1TDO2EGFRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127418-A1 | HETEROCYCLES USEFUL AS IDO AND TDO INHIBITORS | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127418-A1 | HETEROCYCLES USEFUL AS IDO AND TDO INHIBITORS | IDO1, IDO2, TDO2 | IDO1 1/4885TDO2 3/4885EGFR 2995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.